Announced Date: 2024-08-07 (August 7, 2024)
Asset Name: CN201
Licensor: Curon (Curon Biopharmaceutical , China)
Licensee (Buyer): MSD （Merck & Co., Inc，USA）
.
Asset Modality: T-cell-engager bispecific antibody
Asset Target: CD3xCD19-targeting
Potential Indication: B-cell associated diseases
Current Stage: Phase 1 and Phase 1b/2 clinical trials
.
Scope of Authority:
MSD through a subsidiary will acquire full global rights to CN201.
.
Deal Detail:
Upfront payment of $700 million,
Development and regulatory milestone payments up to $600 million,
Total up to 1.3 billion.
.
Link:
MSD to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical – MSD
